Ironwood Pharmaceuticals
IRWD
193 hedge funds and large institutions have $1.8B invested in Ironwood Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 64 increasing their positions, 69 reducing their positions, and 29 closing their positions.
582% more call options, than puts
Call options by funds: $6.98M | Put options by funds: $1.02M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 29
0.28% less ownership
Funds ownership: 113.16% → 112.88% (-0.28%)
7% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 69
1% less funds holding
Funds holding: 195 → 193 (-2)
24% less capital invested
Capital invested by funds: $2.36B → $1.8B (-$560M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$37.8M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$27.6M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$21.3M |
| 4 |
BM
Bridger Management
New York
|
+$18.2M |
| 5 |
SPC
Slate Path Capital
New York
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MFN Partners
Boston,
Massachusetts
|
-$36.1M |
| 2 |
Two Sigma Investments
New York
|
-$14.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$12.6M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11.9M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$10.8M |
IRWD Hedge Fund Activity: Q1 2020 in Review
193 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2020, worth a combined $1.8B — down 24% from $2.36B a quarter earlier.
Fund positioning in IRWD was balanced in Q1 2020: 29 funds opened new positions, 29 closed out, 64 added to existing stakes and 69 trimmed.
The largest buyer was Sarissa Capital Management, adding an estimated $37.8M. The largest seller was MFN Partners, cutting an estimated $36.1M.
- 193 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2020, down from 195 in Q4 2019.
- Funds reported $1.8B of Ironwood Pharmaceuticals stock for Q1 2020, down 24% quarter-over-quarter.
- 29 funds opened new Ironwood Pharmaceuticals positions in Q1 2020 and 29 closed out, a net change of 0 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2020 was Sarissa Capital Management, an estimated $37.8M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2020 was MFN Partners, an estimated $36.1M sold.
Based on aggregated 13F filings for Q1 2020.